Collaboration and License Agreement Sample Contracts

REDACTED COPY COLLABORATION AND LICENSE AGREEMENT by and between
Collaboration and License Agreement • October 5th, 2006 • Trubion Pharmaceuticals, Inc • Pharmaceutical preparations • New York
AutoNDA by SimpleDocs
RECITALS
Collaboration and License Agreement • January 27th, 2004 • Cytokinetics Inc
COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • April 11th, 2018 • MorphoSys AG • Pharmaceutical preparations • New York

This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of June 27, 2010 (the “Effective Date”) by and between XENCOR, INC., a Delaware corporation with its principal offices at 111 West Lemon Avenue, Monrovia, CA 91016 (“Xencor”), and MORPHOSYS AG, a German corporation with its principal offices at Lena-Christ-Strasse 48, 82152 Martinsried/Planegg, Germany (“MorphoSys”).

COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • November 5th, 2020 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • Delaware

THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of May 23, 2014 (the “Execution Date”) by and between CYTOMX THERAPEUTICS, INC., a corporation organized under the laws of the State of Delaware, having its principal place of business at 343 Oyster Point Blvd., Suite 100, South San Francisco, CA, 94080-1913 (“CytomX”), and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York, USA 10154 (“BMS”). CytomX and BMS are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York

This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is entered into as of June 18, 2014 (“Effective Date”) by and between Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 1 Main Street, 13th Floor, Cambridge, MA 02142 (“Dimension”), and Bayer HealthCare LLC, a limited liability company organized under the laws of the State of Delaware, with offices at 455 Mission Bay Blvd South, San Francisco, CA 94158 (“Bayer”). Dimension and Bayer are hereinafter referred to individually as a “Party” and collectively as the “Parties.”

Master Collaboration and License Agreement by and between MODERNA THERAPEUTICS, INC. and MERCK SHARP & DOHME CORP. January 12, 2015
Collaboration and License Agreement • November 9th, 2018 • Moderna, Inc. • Biological products, (no disgnostic substances) • New York

This Master Collaboration and License Agreement (this “Agreement”), dated as of January 12, 2015 (the “Effective Date”), is made by and between Moderna Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (“Moderna”), and Merck Sharp & Dohme Corp., a corporation organized and existing under the laws of New Jersey (“Merck”). Each of Moderna and Merck may be referred to herein as a “Party” or together as the “Parties”.

COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN HOMOLOGY MEDICINES, INC. AND NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. DATED NOVEMBER 6, 2017
Collaboration and License Agreement • March 23rd, 2018 • Homology Medicines, Inc. • Pharmaceutical preparations • New York

THIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into this 6th day of November, 2017 (the “Effective Date”), by and between Homology Medicines, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 45 Wiggins Avenue, Bedford, MA 01730 (“HMI”), and Novartis Institutes for BioMedical Research, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 250 Massachusetts Avenue, Cambridge, MA 02139 (“NVS”). HMI and NVS are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

1 EXHIBIT 10.66 GENE THERAPY COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • July 10th, 1998 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • Delaware
BACKGROUND
Collaboration and License Agreement • September 2nd, 2005 • SGX Pharmaceuticals, Inc. • Delaware
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COLLABORATION AND...
Collaboration and License Agreement • November 9th, 2021 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)

This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of May 26, 2015 (the “Effective Date”), is made by and between Editas Medicine, Inc., a Delaware corporation, having a principal place of business at 300 Third Street, First Floor, Cambridge, MA 02142 (“Editas”), and Juno Therapeutics, Inc., a Delaware corporation, having a place of business at 307 Westlake Avenue North, Suite 300, Seattle, WA 98109 (“Juno”).

COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • August 6th, 2013 • Intrexon Corp • Services-commercial physical & biological research • Delaware

THIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of June 6, 2011 (the “Effective Date”) is entered into between HALOZYME, INC., a California corporation (“Halozyme”) and INTREXON CORPORATION, a Virginia corporation (“Intrexon”).

Collaboration and License Agreement between ADC Therapeutics Sarl and Genmab A/S
Collaboration and License Agreement • April 24th, 2020 • ADC Therapeutics SA • Pharmaceutical preparations • New York

This Collaboration and License Agreement (“Agreement”) is made and entered into, effective as of 14 June 2013 (“Effective Date”), by and between ADC Therapeutics Sarl, a Swiss corporation, having its head office at Rue Saint-Pierre 2, Lausanne, 1003, Switzerland (“ADCT”), and Genmab A/S, a Danish corporation, having its principal place of business at [**] (“Genmab”). Genmab and ADCT are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

AMENDMENT to COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • April 24th, 2020 • ADC Therapeutics SA • Pharmaceutical preparations

This Amendment to the Collaboration and License Agreement dated 14 June 2013 between Genmab A/S (“Genmab”) and ADC Therapeutics Sarl (“ADCT”) (hereinafter referred to as the “Agreement”) is entered into with effect from 20 November 2013 by and between Genmab and ADCT (together referred to as “Parties”). All capitalized terms below are as defined in the Agreement.

COLLABORATION AND LICENSE AGREEMENT by and between KYOWA HAKKO KIRIN CO., LTD. and ULTRAGENYX PHARMACEUTICAL INC. Dated August 29, 2013
Collaboration and License Agreement • December 23rd, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York

This Collaboration and License Agreement (this “Agreement”) is made effective as of August 29, 2013 (the “Effective Date”), by and between Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan (“KHK”), and Ultragenyx Pharmaceutical Inc., a company organized and existing under the laws of California, U.S.A., with an address at 60 Leveroni Ct. Novato, CA 94949, U.S.A. (“UGNX”). KHK and UGNX are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”

REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. COLLABORATION AND LICENSE AGREEMENT dated by
Collaboration and License Agreement • July 31st, 2020 • CureVac B.V. • Pharmaceutical preparations

This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is effective as of the 19th of December, 2019 (“Effective Date”) and is entered into by and between:

BETWEEN
Collaboration and License Agreement • April 10th, 2000 • Genome Therapeutics Corp • In vitro & in vivo diagnostic substances • Massachusetts
AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT among CELGENE RIVOT LTD., CELGENE CORPORATION and EPIZYME, INC.
Collaboration and License Agreement • August 6th, 2015 • Epizyme, Inc. • Pharmaceutical preparations • New York

This AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into and made effective as of the 8th day of July, 2015 (the “Effective Date”) among Epizyme, Inc., a Delaware corporation having its principal place of business at 400 Technology Square, 4th Floor, Cambridge, Massachusetts 02139, U.S.A. (“EPIZYME”), Celgene RIVOT Ltd., having its principal place of business at Clarendon House, 2 Church Street Hamilton, HM 11 Bermuda (“CELGENE”), and, solely for the purposes set forth in Section 13.21, Celgene Corporation, a Delaware corporation having its principal place of business at 86 Morris Avenue, Summit, New Jersey 07901 (“PARENT”). EPIZYME and CELGENE are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”

AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT by and between EDITAS MEDICINE, INC. AND JUNO THERAPEUTICS, INC. May 3, 2018
Collaboration and License Agreement • August 7th, 2018 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York

This AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of May 3, 2018 (the “Amendment Date”), is made by and between Editas Medicine, Inc., a Delaware corporation, having a principal place of business at 11 Hurley St, Cambridge, MA 02141 (“Editas”), and Juno Therapeutics, Inc., a Delaware corporation, having a place of business at 400 Dexter Avenue North, Suite 1200, Seattle, WA 98109 (“Juno”) and amends and restates that certain Collaboration and License Agreement by and between Editas and Juno (the “Original Agreement”) dated as of May 26, 2015 (the “Original Agreement Effective Date”).

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between ARVINAS, INC. and PFIZER INC.
Collaboration and License Agreement • September 14th, 2018 • Arvinas Holding Company, LLC • Pharmaceutical preparations • Delaware

This Agreement (this “Agreement”) is effective as of December 22, 2017 (the “Effective Date”), and is entered into by and between Arvinas, Inc., a corporation organized and existing under the laws of Delaware, located at 5 Science Park, 395 Winchester Ave., New Haven, CT 06511 (“Arvinas”) and Pfizer Inc., a corporation organized and existing under the laws of Delaware, located at 235 East 42nd Street, New York, NY 10017 (“Pfizer”).

COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • August 9th, 2023 • Equillium, Inc. • Pharmaceutical preparations • New York

THIS COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is made and entered into effective as of May 22, 2017 (the “Effective Date”), by and between EQUILLIUM, INC., a corporation organized under the laws of the State of Delaware, USA, with its principal office at 2223 Avenida de la Playa, Suite 108, La Jolla, California 92037, USA (“Equillium”), and BIOCON SA, a company organized under the laws of Switzerland with its principal place of business at c/o BDO SA, Rue De l’Avenir 2, 2800 Delemont, Switzerland (“Biocon”).

Enanta has requested that portions of this document be accorded confidential treatment pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended. COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • February 5th, 2013 • Enanta Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts

This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is made as of February 16, 2012 (“Effective Date”), by and between Novartis Institutes for BioMedical Research, Inc., with its principal office at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (“Novartis”) and Enanta Pharmaceuticals, Inc., with its principal office at 500 Arsenal Street, Watertown, Massachusetts 02472 (“Enanta”). Novartis and Enanta are each referred to individually as a “Party” and together as the “Parties.”

AutoNDA by SimpleDocs
DEVELOPMENT, COMMERCIALIZATION COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • September 12th, 2012 • Kalobios Pharmaceuticals Inc • Pharmaceutical preparations • New York
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed.
Collaboration and License Agreement • April 28th, 2022 • CureVac N.V. • Pharmaceutical preparations

​ ​ ​ Section Page ​ ​ ​ 1. Interpretation 3 2. Effective Date 4 3. Amendment and Restatement 4 4. Representations and Warranties 4 5. General Provisions 4 ​ ​ ​ Schedule ​ ​ ​ ​ 1. Amended and Restated 2020 CLA 7

COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN ABGENIX, INC. AND ASTRAZENECA UK LTD DATED AS OF OCTOBER 15, 2003
Collaboration and License Agreement • July 22nd, 2004 • Abgenix Inc • Biological products, (no disgnostic substances) • New York

This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) dated as of October 15, 2003, is entered into by and between, on the one hand, ABGENIX, INC., a Delaware corporation (“ABX”), having a place of business at 6701 Kaiser Drive, Fremont, California 94555, U.S.A., and, on the other hand, ASTRAZENECA UK LTD., a company incorporated in England under no. 3674842 whose registered office is at 15 Stanhope Gate, London, WIK 1LN, England (“AZ”).

COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • April 3rd, 2014 • Kinemed Inc • Services-commercial physical & biological research • Delaware

This COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is effective as of the 12th day of June, 2012 (the “Effective Date”) by and between KineMed, Inc., a Delaware company located at 5980 Horton Street, Suite 470, Emeryville, CA 94608 (“KineMed”) and Glaxo Group Limited, a company organized under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 ONN, England (“GSK”). Each of KineMed and GSK may be referred to herein as a “Party” or collectively as the “Parties”.

COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • May 29th, 2007 • NovaBay Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware

This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of the 29th day of August, 2006 (the “Effective Date”) by and between NovaCal Pharmaceuticals, Inc., a California corporation, having its principal place of business at 5980 Horton Street, Suite 550, Emeryville, California 94608 (“NovaCal”) and Alcon Manufacturing, Ltd., a Texas partnership, having its principal place of business at 6201 S. Freeway, Fort Worth, Texas 76134-2099 (“Alcon”). NovaCal and Alcon are each referred to herein by name or, individually, as a “Party” or, collectively, as “Parties.”

COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • November 4th, 2021 • BICYCLE THERAPEUTICS PLC • Pharmaceutical preparations • New York

This Collaboration and License Agreement (the “Agreement”) is made and entered into effective as of July 9, 2021 (the “Effective Date”) by and between BicycleTx Limited, a company incorporated in England and Wales with a place of business at Building 900, Babraham Research Campus, Cambridge CB22 3AT, UK (“BicycleTx”), and Ionis Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 2855 Gazelle Court, Carlsbad, California 92010, USA (“Ionis”). BicycleTx and Ionis are referred to herein individually as a “Party” and collectively as the “Parties”.

COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • May 5th, 2020 • Incyte Corp • Services-commercial physical & biological research

Zur Vorlage beim Amtsgericht München – Handelsregister – bestätigen wir hiermit hinsichtlich der von dem Vorstand der Gesellschaft am [•] 2020 mit Zustimmung des Aufsichtsrats vom [•] 2020 beschlossenen Kapitalerhöhung über insgesamt € [•], dass wir heute der

COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • January 13th, 2021 • Anchiano Therapeutics Ltd. • Pharmaceutical preparations • New York

THIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of September 13, 2019 (the “Effective Date”) by and between ADT PHARMACEUTICALS, LLC, a company organized and existing under the laws of Delaware and having offices at 31691 Shoal Water Dr. Orange Beach, Alabama 36561 (“ADT”) and ANCHIANO THERAPEUTICS, INC., a company organized under the laws of Delaware and having offices at One Kendall Square, Building 500, Suite 6-106, Cambridge, MA (“Anchiano”). ADT and Anchiano are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS. Collaboration and License Agreement
Collaboration and License Agreement • September 14th, 2006 • Kos Pharmaceuticals Inc • Pharmaceutical preparations • New York

This agreement (“Agreement”) is made and entered into as of November 6, 2005 (the “Execution Date”), by and between Jerini US, Inc., a Delaware corporation (“Jerini”), and Kos Life Sciences, Inc., a Delaware corporation (“Kos”). Jerini and Kos each may be referred to herein individually as a “Party,” or collectively as the “Parties.”

AMENDMENT #8 to the AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances)

This Amendment #8 to the Amended and Restated Collaboration and License Agreement (“Amendment #8”), effective December 18, 2020 (the “Amendment #8 Effective Date”), is by and between Pioneer Hi-Bred International, Inc., with headquarters at 7100 NW 62nd Avenue, PO Box 1014, Johnston, Iowa 50131-1014, USA (“Pioneer”), and Caribou Biosciences, Inc., located at 2929 7th St., Suite 105, Berkeley, California 94710 (“Caribou Bio”) (Caribou Bio and Pioneer, each individually a “Party,” and together the “Parties”).

COLLABORATION AND LICENSE AGREEMENT between TORAY INDUSTRIES, INC. and ACOLOGIX, INC.
Collaboration and License Agreement • November 14th, 2006 • Acologix, Inc. • Pharmaceutical preparations • New York

This COLLABORATION AND LICENSE AGREEMENT (the “Agreement”), effective as of June 9, 2005 (the “Effective Date”), is made by and between Toray Industries, Inc., a Japanese corporation, having a principal place of business at Toray Bldg., 2-1, Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo 103-8666, Japan (“Toray”), and Acologix, Inc., a Delaware corporation, having offices at 3960 Point Eden Way, Hayward, CA 94545, U.S.A. (“Acologix”) (each a “Party,” together the “Parties”)

AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED STATES
Collaboration and License Agreement • March 6th, 2014 • Pozen Inc /Nc • Pharmaceutical preparations • New York

THIS AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED STATES (the “Agreement”) is made and entered into as of November 18, 2013 (the “Amended and Restated Execution Date”), by and between POZEN INC., a Delaware corporation having offices at 1414 Raleigh Road, Suite 400, Chapel Hill, North Carolina (“POZEN”), and ASTRAZENECA AB, a Swedish corporation having an office at SE-431 83, Mölndal, Sweden (“Licensee”). POZEN and Licensee each may be referred to herein individually as a “Party,” or collectively as the “Parties.”

COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • July 14th, 2017 • Exelixis, Inc. • Services-commercial physical & biological research • Delaware

This Collaboration and License Agreement (the “Agreement”) is entered into as of January 30, 2017 (the “Effective Date”), by and between Exelixis, Inc., a Delaware company having an address at 210 East Grand Avenue, South San Francisco, CA 94080, USA (“Exelixis”) and Takeda Pharmaceutical Company Limited, a Japanese corporation with principal offices located at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, JAPAN (“Collaborator”). Exelixis and Collaborator may be referred to herein individually as a “Party” or collectively as the “Parties”.

Time is Money Join Law Insider Premium to draft better contracts faster.